Who is sponsoring NCT00128583?

NCT00128583 is sponsored by CancerVax Corporation.

What condition does NCT00128583 study?

NCT00128583 studies Melanoma (Skin).

What drugs are being tested in NCT00128583?

Interventions: polyvalent melanoma vaccine.

What is the status of NCT00128583?

NCT00128583 is currently UNKNOWN.

Last reviewed 2013-12-18 · How we verify

Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™

NCT00128583 Phase 2 UNKNOWN

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.

Details

Lead sponsor	CancerVax Corporation
Phase	Phase 2
Status	UNKNOWN
Start date	2005-07

Conditions

Melanoma (Skin)

Interventions

polyvalent melanoma vaccine

Primary outcomes

Response

Countries

United States, Australia